The warrant exercise is a routine capital event with no material impact on the stock. Monitor upcoming quarterly earnings and pipeline catalysts for directional signals.
Price Chart
Executive Summary
Ascendis Pharma reported the closing of a warrant exercise window on June 29, 2026, resulting in the issuance of 177,267 ordinary shares at an average cash consideration of approximately $121.57 per share. The company's share capital increased to DKK 66,189,926, and the articles of association were amended accordingly. This is a routine administrative filing with no material impact on the company's operations or financial outlook.
Key Facts
- 177,267 ordinary shares issued upon exercise of warrants at an average cash consideration of approximately $121.57 per share.
- Share capital increased to DKK 66,189,926.
- Articles of association amended to reflect the capital increase.
- Exercise window closed on June 29, 2026.
Financial Impact
Approximately $21.5 million in cash proceeds from warrant exercises, negligible dilution relative to $16.6B market cap.
Risk Factors
- Minimal dilution from share issuance, but immaterial at current scale.
- No new business or pipeline updates in this filing.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 5 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 6-K Filing (Primary) | 0001193125-26-288414 |
| Document: d22299d6k.htm | 0001193125-26-288414 |
| Document: 0001193125-26-288414-index-headers.html | 0001193125-26-288414 |
| Document: 0001193125-26-288414-index.html | 0001193125-26-288414 |
| Document: 0001193125-26-288414.txt | 0001193125-26-288414 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Sep 9, 2026 23d ago | Insider Cluster | $260.81 $247.69 | ▼ −5.03% | ▼ −4.37% | $227.23 (−12.88%) |
Aug 31, 2026 4w ago | 6-K | $260.25 $260.81 | ▲ +0.22% | ▲ +0.13% | $227.23 (−12.69%) |
Aug 27, 2026 5w ago | ANALYST-UPGRADE | $249.36 $271.12 | ▲ +8.73% | ▲ +8.46% | $227.23 (−8.87%) |
Aug 19, 2026 6w ago | ANALYST-UPGRADE | $259.62 $250.25 | ▼ −3.61% | ▼ −3.22% | $227.23 (−12.48%) |
Aug 19, 2026 6w ago | Insider Buy | $259.62 $250.25 | ▼ −3.61% | ▼ −3.22% | $227.23 (−12.48%) |
Aug 13, 2026 7w ago | 6-K | $246.23 $254.81 | ▲ +3.48% | ▲ +5.45% | $227.23 (−7.72%) |
Aug 13, 2026 7w ago | Press Release | $246.23 $254.81 | ▲ +3.48% | ▲ +5.45% | $227.23 (−7.72%) |
Aug 6, 2026 8w ago | 6-K | $249.85 $246.23 | ▼ −1.45% | ▼ −2.66% | $227.23 (−9.05%) |
Aug 6, 2026 8w ago | Press Release | $249.85 $246.23 | ▼ −1.45% | ▼ −2.66% | $227.23 (−9.05%) |
Jul 15, 2026 11w ago | 6-K | $259.80 $252.66 | ▼ −2.75% | ▼ −1.08% | $227.23 (−12.54%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access